Fig. 1 · Structure

Documents & Downloads

Lamotrigine

Cat. No. A11873 CAS 84057-84-1
Lamotrigine is a novel anticonvulsant drug for inhibition of 5-HT with IC50 of 240 μM and 474 μM in human platelets and rat brain synaptosomes, and also is a sodium channel blocker.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Sodium channel N/A
5-HT (human platelets) 240 μM
5-HT (rat brain synaptosomes) 474 μM

Lamotrigine Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Lamotrigine from 3 published references. In vivo models include Scn1a +/− mice.

Lamotrigine In Vitro Studies

Lamotrigine was continuously superfused onto HEK293 cells transfected with TRESK. At 100 μM, Lamotrigine blocked TRESK-mediated background currents by 46.9 ± 8.1%. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Lamotrigine Blockade of TRESK-Mediated Background Currents

Cell-based study · HEK293 cells transfected with TRESK; n = 6 [1]

In HEK293 cells transfected with TRESK, continuously superfused Lamotrigine at 100 μM blocked TRESK-mediated background currents by 46.9 ± 8.1%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TRESK-mediated background currentsTRESK-mediated background currents 100 μM: 46.9 ± 8.1%[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Method
continuously superfused with a microperfusion system
Reported limits
Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: Lamotrigine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Participation of TRESK channels in sensory neuron excitability (S33); Methods > Electrophysiology in transfected cells (S142); Figure 4 legend (S226, S228)

TRESK-mediated background currents: TRESK-mediated background currents; comparator: resting background currents — Results > Participation of TRESK channels in sensory neuron excitability (S33)

Lamotrigine In Vivo Studies

In male Shank3 KO mice, acute intraperitoneal Lamotrigine administration decreased exploration preference in the textured zone. In a separate study in male Shank3 KO mice, acute intraperitoneal Lamotrigine injection produced no difference in NREM sleep bout length compared with vehicle. In naïve Scn1a +/− mice, Lamotrigine administered through supplemented chow completely prevented lethality compared with untreated mice. [2,3]

Lamotrigine and textured-zone exploration in Shank3 KO mice

Animal study · 8–12-week male Shank3 KO; C57BL/6J background; n = 9 mice for all groups [2]

In male Shank3 KO mice, acute intraperitoneal Lamotrigine administration decreased exploration preference in the textured zone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
discrimination score for the textured zoneReported result decreased exploration preference in the textured zone in Shank3 KO mice after LTG acute administration[2]

Conditions shared by the study groups

Route
intraperitoneal injected
Treatment course
acute administration
Vehicle
2% DMSO in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lamotrigine 20 mg/kgvehicledecreased exploration preference in the textured zone in Shank3 KO mice after LTG acute administration[2]
Lamotrigine 20 mg/kg
Model: 8–12-week male Shank3 KO; C57BL/6J background; n = 9 mice for all groups
Methods and source locations

Compound reported in the paper: Lamotrigine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

STAR★Methods > Experimental model and study participant details > Animal studies (S121); STAR★Methods > Method details > Behavioral tests (S195); Figure 5 legend (S307)

discrimination score for the textured zone: discrimination score for the textured zone; comparator: vehicle — Figure 5 legend (S307)

Lamotrigine 20 mg/kg · STAR★Methods > Method details > Behavioral tests (S195); Figure 5 legend (S307)

Survival in Scn1a +/− Mice During Lamotrigine Treatment

Animal study · Scn1a +/− mice [3]

Lamotrigine (125 mg per kg of chow); naïve Scn1a +/− mice; Treatment began at P18 and survival was monitored until P42. Lamotrigine treatment significantly improved survival compared to untreated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
6‐week survivalReported result Lamotrigine (125 mg per kg of chow); naïve Scn1a +/− mice; Treatment began at P18 and survival was monitored until P42. Lamotrigine treatment completely prevented lethality compared to only 68% (15/22) of untreated animals surviving to P42.[3]

Conditions shared by the study groups

Route
orally through supplementation in chow
Treatment course
Treatment began at P18 and survival was monitored until P42
Vehicle
Purina 5LOD
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lamotrigine 125 mg per kg of chowuntreated Scn1a +/− miceLamotrigine (125 mg per kg of chow); naïve Scn1a +/− mice; Treatment began at P18 and survival was monitored until P42. Lamotrigine treatment completely prevented lethality compared to only 68% (15/22) of untreated animals surviving to P42.[3]
Lamotrigine 125 mg per kg of chow
Model: Scn1a +/− mice
Methods and source locations

Compound reported in the paper: Lamotrigine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Spontaneous seizure frequency monitoring (S54, S55); Results > Survival analysis (S155, S156, S157); Figure 7 legend (S206, S210)

6‐week survival: 6‐week survival; comparator: untreated Scn1a +/− mice — Materials and Methods > Spontaneous seizure frequency monitoring (S55); Results > Survival analysis (S156, S157); Figure 7 legend (S206, S210)

Lamotrigine 125 mg per kg of chow · Materials and Methods > Spontaneous seizure frequency monitoring (S54, S55); Results > Survival analysis (S157); Figure 7 legend (S206, S210)

Lamotrigine and NREM sleep bouts in Shank3 KO mice

Animal study · 8–12-week male Shank3 KO; C57BL/6J background; n = 8 mice for all groups [2]

In male Shank3 KO mice, acute intraperitoneal Lamotrigine injection produced no difference in NREM sleep bout length compared with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NREM sleep bout lengthReported result no difference following LTG acute injection in Shank3 KO mice[2]

Conditions shared by the study groups

Route
intraperitoneal injected
Treatment course
acute injection
Vehicle
2% DMSO in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lamotrigine 20 mg/kgvehicleno difference following LTG acute injection in Shank3 KO mice[2]
Lamotrigine 20 mg/kg
Model: 8–12-week male Shank3 KO; C57BL/6J background; n = 8 mice for all groups
Methods and source locations

Compound reported in the paper: Lamotrigine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

STAR★Methods > Experimental model and study participant details > Animal studies (S121); STAR★Methods > Method details > Stereotaxic surgery (S178, S181); STAR★Methods > Method details > Behavioral tests (S195); Figure 5 legend (S307)

NREM sleep bout length: NREM sleep bout length; comparator: vehicle — Figure 5 legend (S307)

Lamotrigine 20 mg/kg · STAR★Methods > Method details > Behavioral tests (S195); Figure 5 legend (S307)

Specifications

Manufacturer Adooq Bioscience
Actions Blocker
CAS Number 84057-84-1
Formula C9H7Cl2N5
Molecular Weight 256.09
SMILES
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 9 mg/mL (35.14 mM)
Water Insoluble
Ethanol 3 mg/mL (11.71 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
0.5% methylcellulose

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Lamotrigine Research References

  1. [1] Tulleuda A, Cokic B, Callejo G, et al. TRESK channel contribution to nociceptive sensory neurons excitability: modulation by nerve injury. Mol Pain (2011). PMID: 21527011 DOI: 10.1186/1744-8069-7-30 Source material
  2. [2] Guo B, Liu T, Choi S, et al. Restoring thalamocortical circuit dysfunction by correcting HCN channelopathy in Shank3 mutant mice. Cell Rep Med (2024). PMID: 38670100 DOI: 10.1016/j.xcrm.2024.101534 Source material
  3. [3] Hawkins NA, Anderson LL, Gertler TS, et al. Screening of conventional anticonvulsants in a genetic mouse model of epilepsy. Ann Clin Transl Neurol (2017). PMID: 28491900 DOI: 10.1002/acn3.413 Source material

Added to your cart

View Cart Checkout
Loading...